After a parliamentary debate in the House of Commons regarding making Orkambi available to patients with cystic fibrosis (CF), MPs have now written to the company calling on them to show “the utmost urgency to proceed with negotiations”.
The debate comes after Vertex had rejected a counter-proposal by NHS England, in regards to the price that the service was prepared to pay for treatment was rejected by Vertex.
Orkambi is able to treat about 40% of patients with CF, compared to its breakthrough treatment, Kalydeco, which can only treat 5% of patients.
Original Article: UK Ministers call on Vertex to speed up price negotiations